NEW YORK — Japanese diagnostics developer Sysmex reported on recently a 5 percent increase in total sales for the first half of its fiscal year 2020 amid sales growth in domestic and international markets.
For the six-month period ended Sept. 30, Sysmex's total sales grew to ¥142.99 billion ($1.31 billion) from ¥136.19 billion in the same period last year. Sales in Japan were up 8 percent to ¥22.7 million from ¥20.9 million, in part due to higher instrument sales in the hematology field, while overseas sales climbed 4 percent to ¥120.30 billion from ¥115.26 billion.
Sysmex posted an H1 profit of ¥17.59 billion, or ¥84.20 per share, versus ¥19.47 billion, or ¥93.19 per share, a year earlier.
R&D spending rose 19 percent to ¥10.46 billion from ¥8.76 billion, while SG&A costs edged up slightly to ¥40.03 billion from ¥39.79 billion.
During the first half of the year, Sysmex received Japanese manufacturing and marketing approval for the OncoBEAM RAS Colorectal Kit, which tests for mutations in the RAS gene in blood-based circulating tumor DNA, and launched its PS-10 sample prep system for flow cytometry in the US and Canada.
At the end of September, Sysmex had cash and cash equivalents totaling ¥56.99billion.
Looking ahead, the company said it anticipates net sales of ¥310.00 billion for the full fiscal year ending March 31, 2020, with an operating profit of ¥60.00 billion.